These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 37204738)
1. Measuring Emicizumab Levels in the Hemostasis Laboratory. Kershaw G; Dix C Methods Mol Biol; 2023; 2663():589-595. PubMed ID: 37204738 [TBL] [Abstract][Full Text] [Related]
2. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A. Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578 [TBL] [Abstract][Full Text] [Related]
3. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050 [No Abstract] [Full Text] [Related]
4. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146 [TBL] [Abstract][Full Text] [Related]
5. [Emicizumab: a paradigm shift in hemophilia treatment]. Nogami K Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821 [TBL] [Abstract][Full Text] [Related]
6. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389 [TBL] [Abstract][Full Text] [Related]
7. Expert opinion paper on the treatment of hemophilia a with emicizumab. López-Jaime FJ; Benítez O; Díaz Jordán BL; Montaño A; Coll J; Quintana París L; Gómez-Del Castillo Solano MDC Hematology; 2023 Dec; 28(1):2166334. PubMed ID: 36636993 [TBL] [Abstract][Full Text] [Related]
8. Chromogenic Factor VIII Assay for Patients with Hemophilia A and on Emicizumab Therapy. Yacoub OA; Duncan EM Methods Mol Biol; 2023; 2663():597-610. PubMed ID: 37204739 [TBL] [Abstract][Full Text] [Related]
9. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595 [TBL] [Abstract][Full Text] [Related]
10. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays. Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433 [TBL] [Abstract][Full Text] [Related]
11. Hemophilia A: Emicizumab monitoring and impact on coagulation testing. Nardi MA Adv Clin Chem; 2023; 113():273-315. PubMed ID: 36858648 [TBL] [Abstract][Full Text] [Related]
12. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A. Díaz-Ricart M; Isola IM; Escolar G Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480 [TBL] [Abstract][Full Text] [Related]
13. Emicizumab for hemophilia A without inhibitors. Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012 [No Abstract] [Full Text] [Related]
14. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A. Le Quellec S Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331 [TBL] [Abstract][Full Text] [Related]
15. [Hemostatic management of hemophilia]. Tokugawa T Rinsho Ketsueki; 2022; 63(9):1212-1222. PubMed ID: 36198547 [TBL] [Abstract][Full Text] [Related]
16. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801 [TBL] [Abstract][Full Text] [Related]
17. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation. Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963 [TBL] [Abstract][Full Text] [Related]
19. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X. Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Reyes A; Révil C; Niggli M; Chebon S; Schlagmüller S; Flacke JP; Zortel M; Paz-Priel I; Asikanius E; Hampton R; Mahajan A; Schmidt E; Edwards SC Curr Med Res Opin; 2019 Dec; 35(12):2079-2087. PubMed ID: 31355677 [No Abstract] [Full Text] [Related] [Next] [New Search]